No. 2

Mar. 2019 Vol. 39

红杏丸治疗高脂血症临床研究 及其对 $TNF - \alpha$ 、IL - 6、ET - 1 的影响

张健俊1 刘文洲2** 欧莉3

(1. 咸阳市城投医疗集团风轮医院,陕西 咸阳 712000;2. 西电集团医院,陕西 西安 710077;3. 陕西中医药大学,陕西 咸阳 712046)

摘 要: 月的 探讨红杏丸治疗高脂血症的临床疗效及其对肿瘤坏死因子(TNF-a)、白介素-6(IL-6)、内皮素-1(ET-1)指标的影响。方 & 采用随机、双盲、平行对照的试验设计方法,将纳入我院 2017 年 9 月~10 月的 112 例高脂血症患者按照 1:1 的比例进行随机分组,治疗组与对照组各 56 例,其中治疗组给予红杏丸,对照组给予安慰剂,疗程 60 天。在试验过程中,治疗组脱落 4 例,对照组脱落 5 例,最终进入统计分析的例数,治疗组 52 例,对照组 51 例。试验结束揭盲后,分析红杏丸治疗高血脂症患者疗效以及对 TNF-a、IL-6 和 ET-1 指标的影响。 结果 治疗组总胆固醇、甘油三酯及高密度脂蛋白的有效率为 59.62%、55.77% 和 51.92%,明显高于安慰剂对照组的 9.80%、3.92% 和 19.61%;治疗组 TC、TG 值显著低于对照组,而 HDL-C 值明显高于对照组;且 ET-1 及炎性因子 TNF-a、IL-6 均低于安慰剂对照组,具有统计学意义。 结论 红杏丸不仅可以有效调节高脂血症患者的血脂水平,还可以通过降低 TNF-a、IL-6、ET-1 以保护血管内皮功能及改善炎症反应。

关键词:红杏丸;高脂血症;临床研究;血管内皮功能

中图分类号: R589.2 文献标识码: A 文章编号: 1672 - 0571 (2019) 02 - 0096 - 05

DOI:10.13424/j. cnki. mtcm. 2019.02.029

Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF – α , IL – 6 and ET – 1

Zhang Jianjun¹ Liu Wenzhou² Ou Li³

- (1. Fenglun Hospital of Xianyang City Investment Medical Group, Xianyang China, 712000;
- 2. Xi'an XD Group Hospital, Xi'an China, 710007; 3. Shaanxi University of Chinese Medicine, Xianyang China, 712046)

Abstract Objective To explore the clinical efficacy of Hongxing Pill in the treatment of hyperlipidemia and its effects on tumor necrosis factor (TNF – α), interleukin – 6 (IL – 6) and endothelin – 1 (ET – 1). Method A randomized, double – blind, parallel – controlled trial design method was used to randomize 112 patients with hyperlipidemia who were included in our hospital from September to October 2017 according to a 1:1 ratio. The treatment group and the control group each had 56 cases. The treatment group was given Hongxing Pills, and the control group was given a placebo for 60 days. In the course of the experiment, there were 4 cases failed in the treatment group and 5 cases in the control group. Finally, there were 52 cases in the treatment group and 51 cases in the control group. After the blindness was un-

^{*} 基金项目:陕西省秦岭中草药应用开发工程技术研究中心项目(2008ZDGC-32)

^{**} 通讯作者:刘文洲,副主任医师。E-mail:1744007342@qq.com